Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect.

Eli Lilly missed analysts’ revenue expectations by 6% last quarter, reporting revenues of $11.44 billion, up 20.4% year on year. It was a softer quarter for the company, with a significant miss of analysts’ EPS estimates.

Is Eli Lilly a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Eli Lilly’s revenue to grow 45% year on year to $13.56 billion, improving from the 28.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.11 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Eli Lilly has missed Wall Street’s revenue estimates three times over the last two years.

Looking at Eli Lilly’s peers in the branded pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Pfizer delivered year-on-year revenue growth of 21.9%, beating analysts’ expectations by 3%, and Johnson & Johnson reported revenues up 5.3%, in line with consensus estimates. Johnson & Johnson traded down 1% following the results.

Read our full analysis of Pfizer’s results here and Johnson & Johnson’s results here.

There has been positive sentiment among investors in the branded pharmaceuticals segment, with share prices up 2.7% on average over the last month. Eli Lilly is up 6.8% during the same time and is heading into earnings with an average analyst price target of $972.57 (compared to the current share price of $840.50).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.